Threshold Pharma, ATOMIC Initiate First Phase 2 Trial of TH-4000 in Patients with Advanced EGFR-Mutant, T790M-NSCLC

By: via Benzinga
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the company, in collaboration with the Academic Thoracic Oncology ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.